Case Details
- Citation: [2013] SGHC 2
- Court: High Court of the Republic of Singapore
- Date: 10 January 2013
- Judge: Choo Han Teck J
- Coram: Choo Han Teck J
- Case Title: Biomedia Pharma Pte Ltd (formerly known as Malaysia Chemist Pte Ltd) v TAC Distribution Pte Ltd (trading as Trane Singapore) (Amcrotech Pte Ltd, third party)
- Case Number: Suit No 143 of 2009 (assessment of damages)
- Tribunal/Court Stage: Assessment of damages following liability judgment
- Parties: Biomedia Pharma Pte Ltd (plaintiff/applicant); TAC Distribution Pte Ltd (trading as Trane Singapore) (defendant/respondent); Amcrotech Pte Ltd (third party)
- Legal Area: Contract – Remedies – Damages
- Plaintiff/Applicant: Biomedia Pharma Pte Ltd (formerly known as Malaysia Chemist Pte Ltd)
- Defendant/Respondent: TAC Distribution Pte Ltd (trading as Trane Singapore)
- Third Party: Amcrotech Pte Ltd
- Decision Type: Quantum decision on assessment of damages
- Previous Liability Judgment Date: 8 November 2010 (judgment in favour of plaintiff for breach of contract; damages to be assessed)
- Quantum Hearing Date: July 2012
- Verdict on Quantum Date: 24 September 2012
- Counsel for Plaintiff: Mansurhusain Akbar Hussein (Jacob Mansur & Pillai)
- Counsel for Plaintiff (additional): Niru Pillai
- Counsel for Defendant: Niru Pillai (Global Law Alliance LLC)
- Counsel for Third Party: Michael Chia Peng Chuang (Pereira & Tan LLC)
- Judgment Length: 2 pages, 565 words
- Cases Cited: [2013] SGHC 2 (as provided in metadata)
- Statutes Referenced: None stated in the provided extract
Summary
Biomedia Pharma Pte Ltd v TAC Distribution Pte Ltd (trading as Trane Singapore) concerned damages arising from a breach of contract relating to the design and installation of a specialised air-conditioning system for a pharmaceutical factory. The High Court had earlier found that TAC Distribution breached the contract and ordered that damages be assessed. In the assessment stage, the court focused on the proper valuation of the plaintiff’s losses, including whether the plaintiff could recover both a refund of the contract payment and additional general damages for the consequences of the breach.
The court awarded Biomedia a total of $185,000. This comprised $135,000 as reimbursement of the sum paid to the defendant, and an additional $50,000 in general damages. While the defendant argued that the plaintiff should not receive a refund and still recover general damages, the court accepted that the breach had both a clearly proved financial component (the payment) and a non-precisely quantifiable component (inconvenience and trouble), which warranted an additional award. The court also recognised that the breach was a probable contributor to the plaintiff’s closure of its business, but it did not assume that all business loss could be wholly attributed to the defendant’s breach.
What Were the Facts of This Case?
Biomedia Pharma Pte Ltd leased a factory building to carry on its pharmaceutical business. The business required the factory to be used as a “dry laboratory”, which in turn depended on regulatory approval. TAC Distribution Pte Ltd, which was a specialist in air-conditioning systems, contracted to design and install a specialised air-conditioning system for Biomedia’s factory. The installation work was carried out by a third party, Amcrotech Pte Ltd, but the contractual responsibility for the system’s compliance and performance lay with TAC Distribution as the contracting party.
After the system was installed, it became clear that the system did not comply with the contractual requirements. The breach had regulatory consequences: the Health Sciences Authority withheld the grant of a licence to Biomedia to use the factory as a dry laboratory. This regulatory withholding directly affected Biomedia’s ability to operate the facility for its intended pharmaceutical purposes.
In the earlier liability phase, the High Court found in favour of Biomedia for breach of contract. The defendant’s counterclaim and the third-party action were dismissed. The court then ordered that damages be assessed. The assessment of damages was subsequently heard in July 2012, and the court delivered its verdict on quantum on 24 September 2012, culminating in the decision dated 10 January 2013.
During the assessment, it was not disputed that Biomedia had paid TAC Distribution $135,000. The defendant’s position was not that the payment was not made, but that there was no “failure of consideration” that would justify a refund. In other words, TAC Distribution sought to resist the reimbursement component of damages while maintaining that Biomedia should not be compensated in a way that effectively returned the contract payment and also provided additional general damages.
What Were the Key Legal Issues?
The principal legal issue was how to quantify damages for breach of contract where the plaintiff had paid a sum for a specialised system that failed to meet contractual specifications, and where the breach had consequential effects on the plaintiff’s regulatory approval and business operations. The court had to determine whether the plaintiff was entitled to reimbursement of the contract payment and, if so, whether that reimbursement could coexist with an award of general damages.
A second issue concerned the relationship between special and general damages. The court noted that certain claims were special damages that had not been pleaded, and therefore could not be awarded. This raised the question of what losses were properly recoverable on the pleadings and what losses could be treated as general damages—losses that are real but not capable of precise calculation.
Finally, the court had to consider causation and attribution. Even though the breach contributed to the Health Sciences Authority withholding the licence and was a probable contributor to Biomedia’s closure of its business, the court needed to decide how much of the plaintiff’s broader business loss could fairly be attributed to the defendant’s breach, rather than to other factors.
How Did the Court Analyse the Issues?
Choo Han Teck J approached the assessment by distinguishing between different heads of loss and by focusing on what was “clearly proved” versus what required a more evaluative approach. The court agreed with the defendant’s position in part: it accepted that the plaintiff’s other claims were special damages that had not been pleaded, and therefore could not be awarded. This reflects a strict adherence to procedural requirements in damages pleading, ensuring that parties are not awarded unpleaded categories of loss.
On the reimbursement component, the court treated the $135,000 payment as a loss element that was straightforward and supported by the evidence. The payment was not disputed, and the court found that TAC Distribution had failed to hand over a system that complied with the contract. In that context, the court considered the payment to be recoverable as reimbursement. Importantly, the court did not accept the defendant’s argument framed around “failure of consideration” as the decisive factor; instead, it treated the breach and the non-compliance as making the reimbursement element appropriate. The breach had a direct and demonstrable impact: it led to the Health Sciences Authority withholding the licence necessary for Biomedia to use the factory as a dry laboratory.
Turning to general damages, the court addressed the defendant’s argument that Biomedia should not receive both a refund and general damages. The court agreed with the defendant only to the extent that unpleaded special damages were concerned. However, it rejected the broader contention that reimbursement and general damages were mutually exclusive. The court reasoned that the plaintiff’s loss had two components: (1) a clearly proved financial component—the $135,000 payment—and (2) a general damage component that was not amenable to precise assessment, namely the inconvenience and trouble endured because of the breach.
The court’s approach to valuing general damages was explicitly structured. It recognised that the court must take into account the nature of the business, the consequence of the breach, the nature and size of the contract, and the nature of the breach. This indicates that the court did not treat general damages as a purely discretionary or arbitrary figure; rather, it treated them as an evaluative estimate grounded in relevant contextual factors. The court also addressed causation carefully. It did not assume that the plaintiff’s loss in business could be wholly attributed to TAC Distribution’s breach. Instead, the breach was a probable contribution to the plaintiff’s closure. The court then asked how to value that probabilistic contribution. While the extract does not provide a detailed mathematical or doctrinal formula, it shows that the court used a reasoned, fact-sensitive estimate rather than an all-or-nothing attribution.
Applying these principles, the court added $50,000 as general damages to the reimbursement amount, bringing the total award to $185,000. The reasoning demonstrates a pragmatic balance: the court ensured that the plaintiff was compensated for the proven financial loss and also recognised the real but non-quantifiable harms arising from the breach, while avoiding over-attribution of business failure to the defendant.
What Was the Outcome?
The High Court awarded Biomedia a total of $185,000 in damages. Specifically, it ordered $135,000 as reimbursement of the sum paid by Biomedia to TAC Distribution, and $50,000 as general damages for the inconvenience and trouble caused by the breach of contract.
The practical effect of the decision is that TAC Distribution remained liable for both the proven monetary loss associated with the non-compliant system and an additional sum reflecting the broader consequences of the breach. The court’s approach also clarifies that, while unpleaded special damages cannot be recovered, general damages may still be awarded where the breach causes real harm that cannot be precisely measured.
Why Does This Case Matter?
This case is useful for practitioners and students because it illustrates how Singapore courts approach damages assessment after a liability finding in a contract dispute involving complex factual consequences. The decision highlights that damages are not assessed solely by reference to whether a payment was made; instead, courts examine the breach’s impact, the evidence supporting each head of loss, and the procedural status of claims (particularly whether special damages were pleaded).
From a doctrinal perspective, the judgment provides a clear example of the coexistence of reimbursement and general damages. The defendant’s argument—that a refund of the contract payment should preclude general damages—was not accepted. The court’s reasoning supports the proposition that different categories of loss can be compensable simultaneously: reimbursement addresses a proven financial component, while general damages address non-quantifiable harms such as inconvenience and trouble. This is particularly relevant in cases where a breach affects regulatory approvals or operational readiness, leading to delays, disruption, and business consequences that are difficult to quantify with precision.
For litigators, the case also underscores the importance of pleading. The court refused to award other claims because they were special damages that had not been pleaded. This serves as a reminder that even where liability is established, the scope of recoverable damages may be constrained by pleading discipline. In addition, the court’s causation analysis—recognising the breach as a probable contributor but not the sole cause of business closure—demonstrates a cautious approach to attribution. Practitioners should therefore expect courts to calibrate damages to the degree of contribution supported by the evidence, rather than automatically awarding damages for all downstream business losses.
Legislation Referenced
- None stated in the provided judgment extract.
Cases Cited
- [2013] SGHC 2
Source Documents
This article analyses [2013] SGHC 2 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.